Shares of ImmuPharma plc (LON:IMM – Get Free Report) shot up 42.2% on Monday . The company traded as high as GBX 5.60 ($0.07) and last traded at GBX 5.60 ($0.07). 25,452,426 shares traded hands during mid-day trading, an increase of 27% from the average session volume of 20,003,797 shares. The stock had previously closed at GBX 3.94 ($0.05).
ImmuPharma Trading Down 20.3 %
The stock has a market capitalization of £19.57 million, a price-to-earnings ratio of -470.00 and a beta of 1.53. The company has a fifty day moving average of GBX 1.92 and a two-hundred day moving average of GBX 1.78.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- How to Find Undervalued Stocks
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Overbought Stocks Explained: Should You Trade Them?
- What Does the Future Hold for Eli Lilly?
- Financial Services Stocks Investing
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
